Legend Biotech Cell Therapy Shows Early Trial Success
Legend Biotech shares rose nearly 30% after early-stage trial data showed its in vivo CAR-T therapy LB2501 achieved a 100% response rate in a high-dose cohort of blood cancer patients. The experimental treatment generates disease-fighting cells directly inside the body to simplify delivery.
Xurve View
Insights:
Xurve View
Legend Biotech Corp shares rose nearly 30% after its experimental in vivo cell therapy showed efficacy in 12 blood cancer patients. The trial data reported on June 2 marks a shift from traditional CAR-T methods that require complex external cell modification. This simplified delivery method could make Legend Biotech a prime acquisition target for larger pharmaceutical players.
